Research ExplorerPublicationsPSCA expression is associated with favorable tumor features ...

PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer

Standard

PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer. / Heinrich, Marie-Christine; Göbel, Cosima; Kluth, Martina; Bernreuther, Christian; Sauer, Charlotte; Schroeder, Cornelia; Möller-Koop, Christina; Hube-Magg, Claudia; Lebok, Patrick; Burandt, Eike; Sauter, Guido; Simon, Ronald; Huland, Hartwig; Graefen, Markus; Heinzer, Hans; Schlomm, Thorsten; Heumann, Asmus.

In: BMC CANCER, Vol. 18, No. 1, 31.05.2018, p. 612.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Heinrich, M-C, Göbel, C, Kluth, M, Bernreuther, C, Sauer, C, Schroeder, C, Möller-Koop, C, Hube-Magg, C, Lebok, P, Burandt, E, Sauter, G, Simon, R, Huland, H, Graefen, M, Heinzer, H, Schlomm, T & Heumann, A 2018, 'PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer', BMC CANCER, vol. 18, no. 1, pp. 612. https://doi.org/10.1186/s12885-018-4547-7

APA

Heinrich, M-C., Göbel, C., Kluth, M., Bernreuther, C., Sauer, C., Schroeder, C., Möller-Koop, C., Hube-Magg, C., Lebok, P., Burandt, E., Sauter, G., Simon, R., Huland, H., Graefen, M., Heinzer, H., Schlomm, T., & Heumann, A. (2018). PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer. BMC CANCER, 18(1), 612. https://doi.org/10.1186/s12885-018-4547-7

Vancouver

Heinrich M-C, Göbel C, Kluth M, Bernreuther C, Sauer C, Schroeder C et al. PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer. BMC CANCER. 2018 May 31;18(1):612. https://doi.org/10.1186/s12885-018-4547-7

Bibtex

@article{c53332d70deb48189d9f9532f8c504ab,
title = "PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer",
abstract = "BACKGROUND: Prostate Stem Cell Antigen (PSCA) is frequently expressed in prostate cancer but its exact function is unclear.METHODS: To clarify contradictory findings on the prognostic role of PSCA expression, a tissue microarray containing 13,665 prostate cancers was analyzed by immunohistochemistry.RESULTS: PSCA staining was absent in normal epithelial and stromal cells of the prostate. Membranous and cytoplasmic PSCA staining was seen in 53.7% of 9642 interpretable tumors. Staining was weak in 22.4%, moderate in 24.5% and strong in 6.8% of tumors. PSCA expression was associated with favorable pathological and clinical tumor features: Early pathological tumor stage (p < 0.0001), low Gleason grade (p < 0.0001), absence of lymph node metastasis (p < 0.0001), low pre-operative PSA level (p = 0.0118), negative surgical margin (p < 0.0001) and reduced PSA recurrence (p < 0.0001). PSCA expression was an independent predictor of prognosis in multivariate analysis (hazard ratio 0.84, p < 0.0001).CONCLUSIONS: The absence of statistical relationship to TMPRSS2:ERG fusion status, chromosomal deletion or high tumor cell proliferation argues against a major role of PSCA for regulation of cell cycle or genomic integrity. PSCA expression is linked to favorable prognosis. PSCA measurement is a candidate for inclusion in multi-parametric prognostic prostate cancer tests.",
keywords = "Journal Article",
author = "Marie-Christine Heinrich and Cosima G{\"o}bel and Martina Kluth and Christian Bernreuther and Charlotte Sauer and Cornelia Schroeder and Christina M{\"o}ller-Koop and Claudia Hube-Magg and Patrick Lebok and Eike Burandt and Guido Sauter and Ronald Simon and Hartwig Huland and Markus Graefen and Hans Heinzer and Thorsten Schlomm and Asmus Heumann",
year = "2018",
month = may,
day = "31",
doi = "10.1186/s12885-018-4547-7",
language = "English",
volume = "18",
pages = "612",
journal = "BMC CANCER",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer

AU - Heinrich, Marie-Christine

AU - Göbel, Cosima

AU - Kluth, Martina

AU - Bernreuther, Christian

AU - Sauer, Charlotte

AU - Schroeder, Cornelia

AU - Möller-Koop, Christina

AU - Hube-Magg, Claudia

AU - Lebok, Patrick

AU - Burandt, Eike

AU - Sauter, Guido

AU - Simon, Ronald

AU - Huland, Hartwig

AU - Graefen, Markus

AU - Heinzer, Hans

AU - Schlomm, Thorsten

AU - Heumann, Asmus

PY - 2018/5/31

Y1 - 2018/5/31

N2 - BACKGROUND: Prostate Stem Cell Antigen (PSCA) is frequently expressed in prostate cancer but its exact function is unclear.METHODS: To clarify contradictory findings on the prognostic role of PSCA expression, a tissue microarray containing 13,665 prostate cancers was analyzed by immunohistochemistry.RESULTS: PSCA staining was absent in normal epithelial and stromal cells of the prostate. Membranous and cytoplasmic PSCA staining was seen in 53.7% of 9642 interpretable tumors. Staining was weak in 22.4%, moderate in 24.5% and strong in 6.8% of tumors. PSCA expression was associated with favorable pathological and clinical tumor features: Early pathological tumor stage (p < 0.0001), low Gleason grade (p < 0.0001), absence of lymph node metastasis (p < 0.0001), low pre-operative PSA level (p = 0.0118), negative surgical margin (p < 0.0001) and reduced PSA recurrence (p < 0.0001). PSCA expression was an independent predictor of prognosis in multivariate analysis (hazard ratio 0.84, p < 0.0001).CONCLUSIONS: The absence of statistical relationship to TMPRSS2:ERG fusion status, chromosomal deletion or high tumor cell proliferation argues against a major role of PSCA for regulation of cell cycle or genomic integrity. PSCA expression is linked to favorable prognosis. PSCA measurement is a candidate for inclusion in multi-parametric prognostic prostate cancer tests.

AB - BACKGROUND: Prostate Stem Cell Antigen (PSCA) is frequently expressed in prostate cancer but its exact function is unclear.METHODS: To clarify contradictory findings on the prognostic role of PSCA expression, a tissue microarray containing 13,665 prostate cancers was analyzed by immunohistochemistry.RESULTS: PSCA staining was absent in normal epithelial and stromal cells of the prostate. Membranous and cytoplasmic PSCA staining was seen in 53.7% of 9642 interpretable tumors. Staining was weak in 22.4%, moderate in 24.5% and strong in 6.8% of tumors. PSCA expression was associated with favorable pathological and clinical tumor features: Early pathological tumor stage (p < 0.0001), low Gleason grade (p < 0.0001), absence of lymph node metastasis (p < 0.0001), low pre-operative PSA level (p = 0.0118), negative surgical margin (p < 0.0001) and reduced PSA recurrence (p < 0.0001). PSCA expression was an independent predictor of prognosis in multivariate analysis (hazard ratio 0.84, p < 0.0001).CONCLUSIONS: The absence of statistical relationship to TMPRSS2:ERG fusion status, chromosomal deletion or high tumor cell proliferation argues against a major role of PSCA for regulation of cell cycle or genomic integrity. PSCA expression is linked to favorable prognosis. PSCA measurement is a candidate for inclusion in multi-parametric prognostic prostate cancer tests.

KW - Journal Article

U2 - 10.1186/s12885-018-4547-7

DO - 10.1186/s12885-018-4547-7

M3 - SCORING: Journal article

C2 - 29855276

VL - 18

SP - 612

JO - BMC CANCER

JF - BMC CANCER

SN - 1471-2407

IS - 1

ER -